Valuation: Geron Corporation

Market Cap 739M 663M 612M 555M 1.04B 70.18B 1.05B 7.34B 2.92B 36.79B 2.77B 2.71B 117B P/E 2026 *
-26.1x
P/E 2027 * 16.9x
Enterprise Value 739M 663M 612M 555M 1.04B 70.18B 1.05B 7.34B 2.92B 36.79B 2.77B 2.71B 117B EV / Sales 2026 *
3.14x
EV / Sales 2027 * 2.17x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 week-7.26%
Current month-6.50%
1 month-8.73%
3 months-22.30%
6 months-24.84%
Current year-12.88%
1 week 1.08
Extreme 1.08
1.19
1 month 1.08
Extreme 1.08
1.27
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Free

Director

6,351 0.0010%
6/30/26 A Free

Director

6,103 0.0010%
5/20/26 A Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-7.26%-10.16%-35.75% 739M
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.59%+0.13%+10.56%+80.06% 54.55B
-1.07%+1.09%+10.56%+102.38% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+0.23%+14.96%+61.29%+51.28% 26.7B
+3.72%-6.23%+26.01%-8.28% 23.36B
Average -0.12%-1.80%+40.40%+136.01% 38.12B
Weighted average by Cap. -0.50%-1.28%+43.07%+155.39%

Financials

2026 *2027 *
Net sales 235M 211M 195M 177M 331M 22.36B 335M 2.34B 929M 11.72B 883M 865M 37.16B 341M 306M 283M 256M 479M 32.39B 485M 3.39B 1.35B 16.98B 1.28B 1.25B 53.84B
Net income -28.18M -25.29M -23.35M -21.18M -39.58M -2.68B -40.07M -280M -111M -1.4B -106M -104M -4.45B 49.18M 44.14M 40.76M 36.96M 69.08M 4.67B 69.93M 489M 194M 2.45B 185M 181M 7.77B
Net Debt - -
Projected Income Statement - Annual - Geron Corporation
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
27/10/26 $1.150 0.00% 6,709,313
26/10/26 $1.150 +2.68% 11,089,634
23/10/26 $1.120 -0.88% 11,233,211
22/10/26 $1.130 -2.59% 7,178,600
21/10/26 $1.160 -6.45% 8,915,716
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Geron Corporation
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.150USD
Average target price
4.250USD
Spread / Average Target
+269.57%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Geron Corporation
  1. Stock Market
  2. Stocks
  3. GERN Stock